A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

PURPOSE: To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for combined INC280 and buparlisib in patients with recurrent glioblastoma with homozygous phosphatase and tensin homolog (PTEN) deletion, mutation or protein loss. METHODS: This multicenter, o...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Bent, Martin, Azaro, Analia, De Vos, Filip, Sepulveda, Juan, Yung, W. K. Alfred, Wen, Patrick Y., Lassman, Andrew B., Joerger, Markus, Tabatabai, Ghazaleh, Rodon, Jordi, Tiedt, Ralph, Zhao, Sylvia, Kirsilae, Tiina, Cheng, Yi, Vicente, Sergio, Balbin, O. Alejandro, Zhang, Hefei, Wick, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938467/
https://www.ncbi.nlm.nih.gov/pubmed/31776899
http://dx.doi.org/10.1007/s11060-019-03337-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938467/
https://www.ncbi.nlm.nih.gov/pubmed/31776899
http://dx.doi.org/10.1007/s11060-019-03337-2

Ejemplares similares